DK2118101T3 - IMIDAZO (1,5-A)-PYRIDinderivater som glutaminylcyclaseinhibitorer - Google Patents
IMIDAZO (1,5-A)-PYRIDinderivater som glutaminylcyclaseinhibitorerInfo
- Publication number
- DK2118101T3 DK2118101T3 DK08717546.9T DK08717546T DK2118101T3 DK 2118101 T3 DK2118101 T3 DK 2118101T3 DK 08717546 T DK08717546 T DK 08717546T DK 2118101 T3 DK2118101 T3 DK 2118101T3
- Authority
- DK
- Denmark
- Prior art keywords
- imidazo
- pyridine derivatives
- glutaminyl cyclase
- cyclase inhibitors
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Gynecology & Obstetrics (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89390307P | 2007-03-09 | 2007-03-09 | |
PCT/EP2008/052799 WO2008110523A1 (en) | 2007-03-09 | 2008-03-10 | Imidazo [1,5-a] pyridine derivatives as inhibitors of glutaminyl cyclase |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2118101T3 true DK2118101T3 (da) | 2013-01-02 |
Family
ID=39456730
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK08717546.9T DK2118101T3 (da) | 2007-03-09 | 2008-03-10 | IMIDAZO (1,5-A)-PYRIDinderivater som glutaminylcyclaseinhibitorer |
Country Status (5)
Country | Link |
---|---|
US (1) | US7803810B2 (da) |
EP (1) | EP2118101B1 (da) |
JP (1) | JP5612860B2 (da) |
DK (1) | DK2118101T3 (da) |
WO (1) | WO2008110523A1 (da) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8202897B2 (en) * | 2007-04-18 | 2012-06-19 | Probiodrug Ag | Inhibitors of glutaminyl cyclases |
JP5675342B2 (ja) * | 2007-04-18 | 2015-02-25 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのシアノグアニジン誘導体 |
ES2468551T3 (es) * | 2007-04-18 | 2014-06-16 | Probiodrug Ag | Derivados de nitrovinil-diamina como inhibidores de la glutaminil ciclasa |
ES2533484T3 (es) * | 2007-04-18 | 2015-04-10 | Probiodrug Ag | Derivados de tiourea como inhibidores de la glutaminil ciclasa |
ES2478673T3 (es) * | 2007-04-18 | 2014-07-22 | Probiodrug Ag | Derivados de tioxoquinazolinona como inhibidores de la glutaminil ciclasa |
US9512082B2 (en) * | 2007-04-18 | 2016-12-06 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
JP5676249B2 (ja) * | 2007-04-20 | 2015-02-25 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのアミノピリジン誘導体 |
CA2696934A1 (en) * | 2007-09-12 | 2010-02-16 | Probiodrug Ag | Transgenic mice |
JP2011511622A (ja) * | 2008-01-14 | 2011-04-14 | プロビオドルグ エージー | グルタミニルシクラーゼ遺伝子のノックアウト変異を有するマウスモデル |
EP3047854B1 (en) | 2008-07-21 | 2018-03-21 | Probiodrug AG | Diagnostic antibody assay |
DK2475428T3 (da) | 2009-09-11 | 2015-09-28 | Probiodrug Ag | Heterocykliske derivater som glutaminylcyklaseinhibitorer |
US20110152341A1 (en) | 2009-12-22 | 2011-06-23 | Probiodrug Ag | Cleavage of b-amyloid precursor protein |
WO2011101433A1 (en) | 2010-02-18 | 2011-08-25 | Probiodrug Ag | Methods of diagnosing inflammatory diseases by determining pyroglutamate-modified mcp-1 and screening methods for inhibitors of glutaminyl cyclase |
AU2012228236B2 (en) | 2011-03-16 | 2016-10-27 | Vivoryon Therapeutics N.V. | Diagnostic antibody assay |
PE20161573A1 (es) | 2014-02-13 | 2017-01-19 | Incyte Corp | Ciclopropilamina como inhibidor de la lsd1 |
US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
RS59534B1 (sr) | 2014-02-13 | 2019-12-31 | Incyte Corp | Ciklopropilamini kao lsd1 inhibitori |
CA2945674A1 (en) | 2014-04-15 | 2015-10-22 | Dow Agrosciences Llc | Metalloenzyme inhibitor compounds as fungicides |
WO2015160664A1 (en) | 2014-04-15 | 2015-10-22 | Dow Agrosciences Llc | Metalloenzyme inhibitor compounds as fungicides |
US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
WO2016097305A1 (en) | 2014-12-19 | 2016-06-23 | Probiodrug Ag | Novel method for the detection of pglu-abeta peptides |
KR102659373B1 (ko) | 2015-04-03 | 2024-04-23 | 인사이트 홀딩스 코포레이션 | Lsd1 저해제로서 헤테로사이클릭 화합물 |
JP6806342B2 (ja) * | 2015-04-10 | 2021-01-06 | ベイジーン リミテッド | インドールアミンとしての新規5又は8−置換イミダゾ[1,5−a]ピリジン類、及び/又はトリプトファン2,3−ジオキシゲナーゼ |
GB201511790D0 (en) * | 2015-07-06 | 2015-08-19 | Iomet Pharma Ltd | Pharmaceutical compound |
AU2016306555B2 (en) | 2015-08-12 | 2021-01-28 | Incyte Holdings Corporation | Salts of an LSD1 inhibitor |
BR112018071602B1 (pt) * | 2016-04-29 | 2024-02-27 | Iomet Pharma Ltd. | Compostos de imidazopiridina substituídos, sua composição e seus usos como inibidores da indolamina 2,3-dioxigenase e/ou triptofano-2,3- dioxigenase |
EP3515914A4 (en) * | 2016-09-24 | 2020-04-15 | BeiGene, Ltd. | NEW IMIDAZO [1,5-A] PYRIDINES SUBSTITUTED IN POSITION 5 OR 8 AS INDOLEAMINE AND / OR TRYPTOPHANE 2,3-DIOXYGENASES |
DK3461819T3 (da) | 2017-09-29 | 2020-08-10 | Probiodrug Ag | Inhibitorer af glutaminylcyklase |
US11472788B2 (en) | 2017-11-25 | 2022-10-18 | Beigene, Ltd. | Benzoimidazoles as selective inhibitors of indoleamine 2,3-dioxygenases |
EP3521308B1 (en) | 2018-01-31 | 2024-03-13 | Vivoryon Therapeutics N.V. | Humanized and de-immunized antibodies |
WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
CN112110853A (zh) * | 2020-09-23 | 2020-12-22 | 海南梵圣生物科技有限公司 | 一种合成3-羟基-2-吡啶甲酸及其衍生物的方法 |
EP4236938A1 (en) * | 2020-11-02 | 2023-09-06 | Merck Sharp & Dohme LLC | Macrocyclic urea orexin receptor agonists |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2101595B (en) | 1981-06-22 | 1985-05-30 | Ciba Geigy Ag | Substituted imidazo(1,5-a)pyridines, process for their manufacture, pharmaceutical preparations containing these compounds and their therapeutic application |
US4444775A (en) * | 1981-06-22 | 1984-04-24 | Ciba-Geigy Corporation | Substituted imidazo[1,5-A]pyridines |
US4409226A (en) * | 1981-10-05 | 1983-10-11 | Schering Corporation | Imidazo[1,5-a]pyridines |
US4470986A (en) * | 1982-12-21 | 1984-09-11 | Ciba-Geigy Corporation | Certain imidazo (1,5-A) pyridine aliphatic carboxylic acid derivatives and their use as selective thromboxane inhibitors |
US5026712A (en) * | 1985-06-05 | 1991-06-25 | Schering Ag | Novel imidazo[1,5-a]pyridines, useful as cardiovascular and CNS agents |
ES2036128B1 (es) | 1991-07-10 | 1993-12-16 | Menarini Lab | Procedimiento para la preparacion de 4-(imidazo)1,5-a)piridin-8l)-1,4-dihidropiridinas. |
US6948038B2 (en) * | 2001-07-24 | 2005-09-20 | Microsoft Corporation | System and method for backing up and restoring data |
GB0226724D0 (en) | 2002-11-15 | 2002-12-24 | Merck Sharp & Dohme | Therapeutic agents |
CN100447142C (zh) * | 2002-11-18 | 2008-12-31 | 诺瓦提斯公司 | 咪唑并[1,5a]吡啶衍生物及治疗醛固酮所介导疾病的方法 |
US8338120B2 (en) * | 2003-05-05 | 2012-12-25 | Probiodrug Ag | Method of treating inflammation with glutaminyl cyclase inhibitors |
WO2004098625A2 (en) | 2003-05-05 | 2004-11-18 | Probiodrug Ag | Medical use of inhibitors of glutaminyl and glutamate cyclases |
US7732162B2 (en) * | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
KR20110059664A (ko) * | 2003-05-05 | 2011-06-02 | 프로비오드룩 아게 | 글루타미닐 및 글루타메이트 사이클라제의 이펙터의 용도 |
ZA200508439B (en) | 2003-05-05 | 2007-03-28 | Probiodrug Ag | Medical use of inhibitors of glutaminyl and glutamate cyclases |
JP5707014B2 (ja) * | 2003-10-15 | 2015-04-22 | プロビオドルグ エージー | グルタミニル、及びグルタミン酸シクラーゼのエフェクターの使用 |
US20050171112A1 (en) * | 2003-11-03 | 2005-08-04 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
US20050137142A1 (en) * | 2003-11-03 | 2005-06-23 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
US7667044B2 (en) * | 2003-11-03 | 2010-02-23 | Probiodrug Ag | Compounds for the treatment of neurological disorders |
AU2005210004B2 (en) * | 2004-02-05 | 2010-10-28 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
FR2883286B1 (fr) | 2005-03-16 | 2008-10-03 | Sanofi Aventis Sa | NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, INHIBITEURS DE FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT |
GB0704100D0 (en) | 2006-03-17 | 2007-04-11 | Vodafone Plc | Improvements in an ehspa architecture |
US20080249083A1 (en) * | 2006-09-21 | 2008-10-09 | Probiodrug Ag | Novel genes related to glutaminyl cyclase |
US8420684B2 (en) * | 2006-11-09 | 2013-04-16 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
WO2008055950A1 (en) * | 2006-11-09 | 2008-05-15 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
JP5523107B2 (ja) * | 2006-11-30 | 2014-06-18 | プロビオドルグ エージー | グルタミニルシクラーゼの新規阻害剤 |
US20080200567A1 (en) * | 2007-01-19 | 2008-08-21 | Probiodrug Ag | In vivo screening models for treatment of alzheimer's disease and other qpct-related disorders |
-
2008
- 2008-03-10 DK DK08717546.9T patent/DK2118101T3/da active
- 2008-03-10 WO PCT/EP2008/052799 patent/WO2008110523A1/en active Application Filing
- 2008-03-10 US US12/045,163 patent/US7803810B2/en active Active
- 2008-03-10 EP EP08717546A patent/EP2118101B1/en active Active
- 2008-03-10 JP JP2009552218A patent/JP5612860B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
WO2008110523A1 (en) | 2008-09-18 |
US20080234313A1 (en) | 2008-09-25 |
JP5612860B2 (ja) | 2014-10-22 |
EP2118101A1 (en) | 2009-11-18 |
JP2010520869A (ja) | 2010-06-17 |
EP2118101B1 (en) | 2012-09-26 |
US7803810B2 (en) | 2010-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2118101T3 (da) | IMIDAZO (1,5-A)-PYRIDinderivater som glutaminylcyclaseinhibitorer | |
DK2137184T3 (da) | Imidazo[1,2-a]pyridinforbindelser som receptor-tyrosinkinaseinhibitorer | |
DK2124944T3 (da) | Pyrazolo[3,4-b]pyridinderivater som phosphodiesteraseinhibitorer | |
DK2160389T3 (da) | Thioxoquinazolinonderivater som glutaminylcyclaseinhibitorer | |
DK2160380T3 (da) | Cyano-guanidin derivater som glutaminyl cyclase inhibitorer | |
DK2201012T3 (da) | Pyrrolo[2,3-d]pyrimidinderivater som proteinkinase b-hæmmere | |
DK2074122T5 (da) | Pyrido (2, 3-d) pyrimidin0n-forbindelser og anvendelse deraf som pi3 inhibitorer | |
DK2142514T3 (da) | Thioureaderivater som glutaminylcyclase-inhibitorer | |
IL204720A0 (en) | Imidazo [1, 2 - a] pyridine derivatives useful as alk inhibitors | |
DK1904494T3 (da) | Imidazo[1,2-A]pyridin-forbindelser som VEGF-R2-inhibitorer | |
DK2094263T3 (da) | 2-adamantyl-butyramidderivater som selektive 11 beta-hsd1-inhibitorer | |
SMT201400123B (it) | Imidazo[1,2B]piridazine sostituite come inibitori di trk-chinasi | |
DK1868999T3 (da) | Pyridin-3-carboxamidderivater som omvendte CB1-agonister | |
DK2142513T3 (da) | Nitrovinyl-diamin-derivater som glutaminyl-cyclase-inhibitorer | |
DK2004654T3 (da) | Pyrazolopyrimidin derivater til anvendelse som kinase antagonister | |
DK1846394T3 (da) | Pyrazolylaminopyridinderivater, der er egnede som kinaseinhibitorer | |
DK2069324T3 (da) | Fusioneret aminopyridin som hsp90-inhibitorer | |
IL197393A0 (en) | Pyridin-4-yl derivatives as immunomodulating agents | |
DK2220070T3 (da) | 2-benzylpyridazinonderivater som Met-kinaseinhibitorer | |
DK2142515T3 (da) | Nitrovinyl-diaminderivater som glutaminyl-cyclase-inhibitorer | |
DK2078001T3 (da) | Diazepan-acetamidderivater som selektive 11-HSD1-inhibitorer | |
DK1711177T3 (da) | 1H-thieno-2,3-c-pyrazolderivater, der er egnede som kinase-I-inhibitorer | |
DE102008005493A8 (de) | 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate | |
ZA201004023B (en) | 7-azaindole derivatives as selective 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors | |
DK2069310T3 (da) | Sulfonylpyrazolin-1-carboxamidin-derivater som 5-HT6-antagonister |